Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details
GS3Economy · S&T · Environment · Security· Industry, investment & MSMEs· Prelims·
Why in news
Wockhardt shares surged 19% following the US FDA approval of ZAYNICH, a fourth-generation cephalosporin designed to combat drug-resistant infections.
Background
ZAYNICH is a fourth-generation cephalosporin that targets multiple penicillin-binding proteins simultaneously. It received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA after the Phase 3 ENHANCE-1 study showed higher clinical cure rates than meropenem for complicated urinary tract infections.
Facts for Prelims
- S&TZAYNICH: A fourth-generation cephalosporin antibiotic targeting multiple penicillin-binding proteins.
- FactZAYNICH received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the US FDA.
- FactENHANCE-1: The Phase 3 study comparing ZAYNICH's clinical cure rate against meropenem.
- PostDrugs Controller General of India: The Indian authority that approved ZAYNICH.
For Mains
Q. Discuss the significance of the Qualified Infectious Disease Product (QIDP) designation in incentivizing pharmaceutical R&D to combat antimicrobial resistance.
Dimensions to cover in your answer
- Market incentive: QIDP and Fast Track designations as catalysts for high-risk antibiotic R&D
- Public health priority: Addressing the clinical gap in treating complicated urinary tract infections and pyelonephritis
Keywords: Antimicrobial Resistance · Pharmaceutical R&D · Clinical Cure Rate · Drug Designations · Biotech Investment
More Economy notes
- India eyes major bond index entry as tax exemptions sweeten appeal · 8 June 2026
- Vande Bharat Sleeper train: RVNL targets December 2026 for first prototype launch · 7 June 2026
- Waste treatment plants will soon turn wealth generating units, says MA&UD Minister Narayana · 7 June 2026
- MEIL-led Zojila tunnel set for final breakthrough on June 9 · 7 June 2026
- Telangana constitutes committee to examine international medical tourism in govt. hospitals · 7 June 2026
- Separate ELEVATE track for Beyond Bengaluru startups welcomed · 7 June 2026
Something wrong, or something missing?
Spotted a mistake in a note, or want a topic, format or PDF that would help your preparation? Write to us. We read every mail and fix errors fast.
Report a mistake →Ask for something →thesatyadheesh@gmail.com
This note is generated automatically from SatyaDheesh's news feed and mapped to the UPSC CSE syllabus. Check facts against the original report or PIB before using them in an answer.